STOCK TITAN
  1. Home
  2. News
  3. DNLI

Denali Therapeutics Inc - DNLI STOCK NEWS

Welcome to our dedicated news page for Denali Therapeutics (Ticker: DNLI), a resource for investors and traders seeking the latest updates and insights on Denali Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Denali Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Denali Therapeutics's position in the market.

News
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Rhea-AI Summary
Denali Therapeutics Inc. reports financial results for Q4 and full year 2023, highlighting significant progress in their therapeutic portfolio and clinical validation of their BBB-crossing TV platform. The company expects to complete enrollment in late-stage trials for MPS II and ALS in 2024, expanding their TV-enabled portfolio for neurodegenerative diseases. Denali also entered into a Collaboration and Development Funding Agreement for a Phase 2a study in Parkinson's disease, anticipating regulatory approval. Financially, the company's net losses decreased, with a focus on operational expenses to extend cash runway into 2028.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.25%
Tags
earnings
-
News
Denali Therapeutics Announces $500 million Private Placement Equity Financing
Rhea-AI Summary
Denali Therapeutics Inc. announced a private investment in public equity (PIPE) financing to issue 3,244,689 shares at $17.07 per share and pre-funded warrants for 26,046,065 shares at $17.06 per share, totaling approximately $500 million. The financing aims to support research, development, and expansion of BBB-crossing Transport Vehicle technology for treating neurodegenerative diseases. Denali expects cash reserves to reach $1.5 billion post-financing, with plans to file a registration statement for the securities sold.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.25%
Tags
none
-
News
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
Rhea-AI Summary
Denali Therapeutics Inc. announces new data presentations highlighting the potential of its BBB-crossing enzyme replacement therapies in development for the treatment of mucopolysaccharidoses (MPS). New clinical data on tividenofusp alfa in MPS II (Hunter syndrome) and mouse model data on DNL126 in MPS IIIA (Sanfilippo syndrome type A) are being presented. The Phase 1/2 study of tividenofusp alfa shows sustained normalization of CSF heparan sulfate, robust, sustained reduction in neurofilament light chain (NfL), and positive treatment effects in brain and somatic tissues. The Phase 1/2 results also demonstrate normalization of liver and spleen volumes, maintenance of normal growth, and sustained reduction of urine heparan sulfate and dermatan sulfate. Dosing has begun in the Phase 1/2 study of DNL126 for the potential treatment of MPS IIIA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
none
News
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
Rhea-AI Summary
Denali Therapeutics Inc. (Nasdaq: DNLI) announced upcoming presentations at the 20th Annual WORLDSymposium™ for its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH). The presentations will include new two-year data on clinical outcomes and preclinical studies of DNL126 in MPS IIIA mice. Denali is also participating in events on strategies for treating the CNS and emerging biomarkers in neurodegenerative lysosomal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
none
-
News
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Rhea-AI Summary
Denali Therapeutics Inc. (DNLI) announced program progress and expected milestones for 2024, including the completion of enrollment in late-stage clinical trials for MPS II and ALS, establishment of commercial readiness, and advancement of a broad clinical-stage portfolio of seven therapeutic product candidates across various diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.27%
Tags
none
-
News
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Denali Therapeutics Inc. (DNLI) Reports Q3 Financial Results, Highlights Progress in Neurodegenerative Disease Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
earnings
News
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
Rhea-AI Summary
Denali Therapeutics announces positive interim data from Phase 1/2 study of DNL310 in MPS II patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
clinical trial
-
News
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
earnings
-
News
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
News
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
none
Stock DNLI logo
Denali Therapeutics Inc

Nasdaq:DNLI

DNLI Rankings

#1786 Ranked by Market Cap
#4172 Ranked by Stock Gains
N/A Ranked by Dividends

DNLI Stock Data

2.54B
120.16M
13.79%
79.49%
6.77%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
South San Francisco

About DNLI

denali therapeutics inc. (“denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including alzheimer’s disease, parkinson’s disease, als and others. denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. founding investors include fidelity biosciences, arch venture partners, flagship ventures and the alaska permanent fund (represented by crestline investors).